M Mansfeld1, A Skrahina2, L Shepherd3, A Schultze3, A M Panteleev4,5, R F Miller6, J M Miro7, I Zeltina8, S Tetradov9,10, H Furrer11, O Kirk1, A Grzeszczuk12, N Bolokadze13, A Matteelli14, F A Post15, J D Lundgren1, A Mocroft3, Amw Efsen1, D N Podlekareva1. 1. CHIP (Centre for Health and Infectious Disease Research), Department of Infectious Diseases, Section 2100, Rigshospitalet - University of Copenhagen, Copenhagen, Denmark. 2. Research Institute of Pulmonology and Pulmonary Tuberculosis, Minsk, Belarus. 3. Department of Infection and Population Health, University College London Medical School, London, UK. 4. TB Hospital #2, St Petersburg, Russia. 5. St Petersburg AIDS Centre, St Petersburg, Russia. 6. Centre for Sexual Health & HIV Research, Mortimer Market Centre, University College London, London, UK. 7. Infectious Diseases Service, Hospital Clinic, University of Barcelona, Barcelona, Spain. 8. Infectology Centre of Latvia, Riga, Latvia. 9. 'Dr Victor Babes' Hospital of Tropical and Infectious Diseases, Bucharest, Romania. 10. 'Carol Davila' University of Medicine and Pharmacy, Bucharest, Romania. 11. Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland. 12. Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland. 13. Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia. 14. Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. 15. King's College Hospital NHS Foundation Trust, London, UK.
Abstract
OBJECTIVES: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE). METHODS: Thirty-eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfected patients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study. RESULTS: Respondent centres in EE comprised: Belarus (n = 3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P < 0.001) and less often provided by the same doctors (41% versus 90%, respectively; P = 0.002), whereas regular screening of HIV-infected patients for TB (80% versus 40%, respectively; P = 0.037) and directly observed treatment (88% versus 20%, respectively; P < 0.001) were more common in EE. The reported availability of rifabutin and second- and third-line anti-TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P < 0.001). CONCLUSIONS: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB-coinfected patients and the availability of anti-TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.
OBJECTIVES: The aim of the study was to investigate the organization and delivery of HIV and tuberculosis (TB) health care and to analyse potential differences between treatment centres in Eastern (EE) and Western Europe (WE). METHODS: Thirty-eight European HIV and TB treatment centres participating in the TB:HIV study within EuroCoord completed a survey on health care management for coinfectedpatients in 2013 (EE: 17 respondents; WE:21; 76% of all TB:HIV centres). Descriptive statistics were obtained for regional comparisons. The reported data on health care strategies were compared with actual clinical practice at patient level via data derived from the TB:HIV study. RESULTS: Respondent centres in EE comprised: Belarus (n = 3), Estonia (1), Georgia (1), Latvia (1), Lithuania (1), Poland (4), Romania (1), the Russian Federation (4) and Ukraine (1); those in WE comprised: Belgium (1), Denmark (1), France (1), Italy (7), Spain (2), Switzerland (1) and UK (8). Compared with WE, treatment of HIV and TB in EE are less often located at the same site (47% in EE versus 100% in WE; P < 0.001) and less often provided by the same doctors (41% versus 90%, respectively; P = 0.002), whereas regular screening of HIV-infectedpatients for TB (80% versus 40%, respectively; P = 0.037) and directly observed treatment (88% versus 20%, respectively; P < 0.001) were more common in EE. The reported availability of rifabutin and second- and third-line anti-TB drugs was lower, and opioid substitution therapy (OST) was available at fewer centres in EE compared with WE (53% versus 100%, respectively; P < 0.001). CONCLUSIONS: Major differences exist between EE and WE in relation to the organization and delivery of health care for HIV/TB-coinfectedpatients and the availability of anti-TB drugs and OST. Significant discrepancies between reported and actual clinical practices were found in EE.
Authors: S Keshavjee; I Y Gelmanova; A D Pasechnikov; S P Mishustin; Y G Andreev; A Yedilbayev; J J Furin; J S Mukherjee; M L Rich; E A Nardell; P E Farmer; J Y Kim; S S Shin Journal: Ann N Y Acad Sci Date: 2007-10-22 Impact factor: 5.691
Authors: D N Podlekareva; D Grint; F A Post; A Mocroft; A M Panteleev; R F Miller; J M Miro; M Bruyand; H Furrer; V Riekstina; E Girardi; M H Losso; J A Caylá; E A Malashenkov; N Obel; A M Skrahina; J D Lundgren; O Kirk Journal: Int J Tuberc Lung Dis Date: 2013-02 Impact factor: 2.373
Authors: Daria N Podlekareva; Amanda Mocroft; Frank A Post; Vija Riekstina; Jose M Miro; Hansjakob Furrer; Mathias Bruyand; Alexander M Panteleev; Aza G Rakhmanova; Enrico Girardi; Marcello H Losso; Javier J Toibaro; Joan Caylá; Rob F Miller; Niels Obel; Alena Skrahina; Nelly Chentsova; Jens D Lundgren; Ole Kirk Journal: AIDS Date: 2009-11-27 Impact factor: 4.177
Authors: Alena Skrahina; Henadz Hurevich; Aksana Zalutskaya; Evgeni Sahalchyk; Andrei Astrauko; Sven Hoffner; Valiantsin Rusovich; Andrei Dadu; Pierpaolo de Colombani; Masoud Dara; Wayne van Gemert; Matteo Zignol Journal: Bull World Health Organ Date: 2012-11-26 Impact factor: 9.408
Authors: A M W Efsen; A Schultze; R F Miller; A Panteleev; A Skrahin; D N Podlekareva; J M Miro; E Girardi; H Furrer; M H Losso; J Toibaro; J A Caylà; A Mocroft; J D Lundgren; F A Post; O Kirk Journal: J Infect Date: 2017-10-20 Impact factor: 6.072
Authors: Anne Marie W Efsen; Anna Schultze; Frank A Post; Alexander Panteleev; Hansjakob Furrer; Robert F Miller; Marcelo H Losso; Javier Toibaro; Aliaksandr Skrahin; Jose M Miro; Joan A Caylà; Enrico Girardi; Mathias Bruyand; Niels Obel; Daria N Podlekareva; Jens D Lundgren; Amanda Mocroft; Ole Kirk Journal: PLoS One Date: 2015-12-30 Impact factor: 3.240
Authors: Russell R Kempker; Nikoloz Chkhartishvili; Inga Kinkladze; Marcos C Schechter; Kristin Harrington; Nino Rukhadze; Lela Dzigua; Tengiz Tserstvadze; Carlos Del Rio; Henry M Blumberg; Nestani Tukvadze Journal: Open Forum Infect Dis Date: 2019-05-17 Impact factor: 3.835
Authors: Gerard de Vries; Sarah van de Berg; Anke van Dam; Sayohat Hasanova; Manish Pareek; Marieke J van der Werf; Daria N Podlekareva Journal: ERJ Open Res Date: 2021-01-18
Authors: Izabella Lecka; Viktoriya Pantyley; Liudmila Fakeyeva; Alexandrina Cruceanu Journal: Int J Environ Res Public Health Date: 2021-04-01 Impact factor: 3.390